Latest news:

Follicum Phase IIa study of FOL-005 against hair loss approved by the German Medicines Agency

Lund, Sweden, February 7, 2018: Follicum AB (“Follicum” or “the company”) today announced it has received approval from the German Medicines Agency (BfArM) and German Ethics Committee to commence a Phase IIa clinical trial in Germany with its lead candidate FOL-005 on patients with Alopecia (hair loss). The trial will include approximately 60 patients and […]

Sign up for our Newsletter

Hair growth

Our drug candidate FOL-005 has, in clinical trials, demonstrated increased hair growth on healthy individuals

Read more

Diabetes

Follicums pre-clinical research has resulted in a new peptide, FOL-014, which increased the release of insulin on mice

Read more

Investors

We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more

Press

News

01 Feb 18
Welcome to our new website!

Our new webpage, www.follicum.com, will make it much easier to access information about our two, mai...

Events

12 Mar 18
BIO Europe Spring

Follicum will attend the BIO Europe Spring Conference 12-14 March 2018 in Amsterdam, The Netherlands...

04 Jun 18
BIO International

Follicum will attend the BIO International Convention 4-7 June 2018 in Boston, USA More information...